Aura Biosciences, Inc.
No enriched coverage for $AURA in the last 7 days.
No SEC Form 4 filings for $AURA in the last 30 days.
BOSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( NASDAQ: AURA ) , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will ...
ROCKVILLE, Md., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- NovaBridge Biosciences ( Nasdaq: NBP ) ( NovaBridge or the Company ) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. ( Visara ) has appointed ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program
